BTIG stays Buy rated on NRx Pharmaceuticals, Inc. (NRXP) as FDA waives additional clinical trials

March 24, 2026 12:58 PM

BTIG analyst Thomas Schrader reiterated a Buy rating and $25.00 price target on NRx Pharmaceuticals, Inc. (NASDAQ: NRXP)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found